Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Jinhee | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Choi, Jong-Ii | - |
dc.contributor.author | Lee, Kwang No | - |
dc.contributor.author | Shim, Jaemin | - |
dc.contributor.author | Ahn, Hyeong Sik | - |
dc.contributor.author | Kim, Young-Hoon | - |
dc.date.accessioned | 2021-09-03T00:04:47Z | - |
dc.date.available | 2021-09-03T00:04:47Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2017-10-23 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81871 | - |
dc.description.abstract | Background Beta-blockers are first-line therapy in patients with congenital long-QT syndrome (LQTS). Objective This study sought to determine the differences in effectiveness of beta-blockers on risk reduction according to LQTS genotype. Methods We searched MEDLINE, EMBASE, and CENTRAL databases to investigate the use of beta-blockers (atenolol, nadolol, propranolol, and metoprolol) in patients with LQTS. Hazard ratio (HR) and relative risk (RR) were extracted or calculated from studies reporting cardiac events (syncope, aborted cardiac arrest (ACA), or sudden cardiac death (SCD)). Results Among 2,113 articles searched, 10 studies (7 registry-based cohort studies (Cohort) and 3 interrupted time series studies (ITS)) involving 9,727 patients were included. In a meta-analysis using a random-effect model, the use of beta-blocker was associated with significant risk reduction of all cardiac events (HR 0.49, p<0.001 in Cohort; RR 0.39, p<0.001 in ITS) and serious cardiac events (ACA or SCD) (HR 0.47, p<0.001 in Cohort). In both LQT1 and LQT2, the risk was reduced with beta-blocker therapy in Cohort (HR 0.59 in LQT1; HR 0.39 in LQT2) as well as ITS (RR 0.29 in LQT1; RR 0.48 in LQT2). Among the beta-blockers, nadolol showed a significant risk reduction in both LQT1 and LQT2 (HR 0.47 and 0.27, respectively), whereas atenolol and propranolol decreased the risk only in LQT1 (HR 0.36 and 0.46, respectively). Metoprolol showed no significant reduction in either genotype. In LQT3, beta-blocker therapy was not as effective as LQT1 or LQT2; however, it was inconclusive due to data insufficiency. Conclusion This meta-analysis showed that beta-blockers were effective in reducing risk of cardiac events in patients with LQTS. Among them, nadolol was effective in LQT1 and LQT2, whereas other drugs showed different effectiveness depending on LQT genotype. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.subject | ABORTED CARDIAC-ARREST | - |
dc.subject | RISK-FACTORS | - |
dc.subject | ADRENERGIC-BLOCKADE | - |
dc.subject | CLINICAL-COURSE | - |
dc.subject | FOLLOW-UP | - |
dc.subject | THERAPY | - |
dc.subject | EFFICACY | - |
dc.subject | REPOLARIZATION | - |
dc.subject | MANAGEMENT | - |
dc.subject | DISPERSION | - |
dc.title | Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Jung | - |
dc.contributor.affiliatedAuthor | Choi, Jong-Ii | - |
dc.contributor.affiliatedAuthor | Lee, Kwang No | - |
dc.contributor.affiliatedAuthor | Shim, Jaemin | - |
dc.contributor.affiliatedAuthor | Ahn, Hyeong Sik | - |
dc.contributor.affiliatedAuthor | Kim, Young-Hoon | - |
dc.identifier.doi | 10.1371/journal.pone.0185680 | - |
dc.identifier.scopusid | 2-s2.0-85032178006 | - |
dc.identifier.wosid | 000413403000008 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.12, no.10 | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 12 | - |
dc.citation.number | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ABORTED CARDIAC-ARREST | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ADRENERGIC-BLOCKADE | - |
dc.subject.keywordPlus | CLINICAL-COURSE | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | REPOLARIZATION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DISPERSION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.